

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

APPOINTMENT OF NEW CHIEF EXECUTIVE OFFICER

The board (the “**Board**”) of directors (“**Directors**”) of Jenscare Scientific Co., Ltd. (the “**Company**”, and its subsidiaries, the “**Group**”) is pleased to announce that:

In order to further facilitate the Group’s internationalization strategy, comprehensively deepen and accelerate global commercialization process, after prudent consideration, Mr. LV Shiwen (“**Mr. Lv**”) informed the Company that he shall resign as the chief executive officer of the Company (the “**Chief Executive Officer**”), and nominated Mr. PAN Fei (“**Mr. Pan**”) as the Chief Executive Officer. The appointment of the Chief Executive Officer was approved unanimously by the nomination committee of the Company and the Board on January 15, 2025.

Mr. Pan, aged 40, joined the Group in January 2021. He is the vice president and chief financial officer of the Group (the “**Chief Financial Officer**”). He has served as the executive director of the Company (the “**Executive Director**”) since May 2021. Mr. Pan has over 15 years of experience in corporate management and investment banking, especially focusing on healthcare industry. He has in-depth understanding and insight in both domestic and overseas healthcare industry. Since joining the Group, Mr. Pan has taken important roles in international business management, business strategy and development, and overall financial management and financing activities. Mr. Pan also acts as director and/or general manager of certain Group’s subsidiaries. Mr. Pan obtained a master’s degree from the University of Cambridge in 2010. Further details of Mr. Pan’s experiences are set out in the Company’s 2023 annual report.

Save as disclosed herein, as at the date of this announcement, Mr. Pan has not held any other positions in the Company or other members of the Group. Mr. Pan has not held any directorship in other listed companies in Hong Kong or overseas in the last three years and does not have any relationship with any directors, senior management or substantial shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”)) of the Company.

Mr. Pan will enter into a service contract for a term of the appointment which coterminous with terms of service on the Board. He is entitled to a remuneration of RMB1.70 million per annum and discretionary bonuses to be determined by the remuneration committee of the Company and the Board. Mr. Pan's remuneration and other benefits are subject to review by the remuneration committee of the Company and the Board from time to time.

As at the date of this announcement, Mr. Pan is interested in 33,452,479 H shares of the Company and 16,363,620 domestic shares of the Company, respectively. The interest includes beneficial interest and interest in controlled corporations. Save for such interest, Mr. Pan did not have, directly or indirectly, any interest in shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Lv has confirmed to the Company that he has no disagreement with the Board and there are no matters relating to his resignation as the Chief Executive Officer that need to be brought to the attention of the shareholders of the Company and the Stock Exchange. Mr. Lv remains as an Executive Director and chairman of the Board. Subsequent to the resignation of Mr. Lv as the Chief Executive Officer, the Company has complied with Code Provision C.2.1 of Part 2 of Appendix C1 regarding the separation of role of chairman of the Board and the Chief Executive Officer under the Listing Rules.

Save as disclosed above, there is no other information required to be disclosed by the Company pursuant to the requirements under the Rules 13.51(2)(h) to (v) of the Listing Rules.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and CEO

Hong Kong, January 15, 2025

As at the date of this announcement, the board of directors of the Company comprises Mr. LV Shiwen and Mr. PAN Fei, as executive Directors; Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing, as non-executive Directors; and Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe, as independent non-executive Directors.